PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)
NCT ID: NCT04974294
Last Updated: 2023-01-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
516 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-28
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To determine the effect of PCV-13 and PPV-23 vaccination versus control on experimental pneumococcal colonisation of 2 clades of serotypes 3 and 6B at 1 month and 6 months post vaccination respectively, using the EHPC model.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT00744263
Pneumonia, Pneumococcal
Pneumococcal Infections
13-valent Pneumococcal Vaccine
COMPLETED
PHASE4
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
NCT06731374
Pneumococcal Disease
Pneumococcal Carriage
RECRUITING
PHASE4
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
NCT01128439
Invasive Pneumococcal Disease
COMPLETED
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT06183216
Pneumococcal Infectious Disease
COMPLETED
PHASE1
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
Pneumococcal Disease
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Streptococcus pneumoniae (SPN) is the leading cause of morbidity and mortality worldwide, causing community acquired pneumonia (CAP), bacterial meningitis and bacteremia. Pneumococcal infections cause over 1 million pneumonia deaths per year in children in the developing world and is a major burden of otitis media globally.
The LSTM Experimental Human Pneumococcal Challenge (EHPC) model is a unique method of measuring pneumococcal colonization of bacteria, understanding the effect of pneumococcal colonization on acquired immunity, and allows vaccines to be tested in adults to understand their effect on colonization in a manner which is cost-effective and uses much smaller numbers of participants compared to large phase III clinical trials.
Participants: Healthy adults aged 18-50 years of age (inclusive) will be recruited. A recruitment target of up to 516 participants with an approximate screen failure/dropout rate of 20% will ensure 410 participants complete Part A and 246 complete Part A \& B of the trial.
Methods: Double blind randomized controlled trial (DBRCT) to investigate the effect of PCV-13 and PPV-23 vaccination on pneumococcal colonisation using the EHPC model in healthy adults. Participants will be randomised to 5 arms for Part A of the study that:
1. to receive PCV-13 vaccine IM and inoculation a month later with SPN3 clade 1a;
2. to receive PCV-13 vaccine IM and inoculation a month later with SPN3 clade 2;
3. to receive PPV-23 vaccine IM and inoculation a month later with SPN3 clade 1a;
4. to receive 0.9% saline for injection IM and inoculation a month later with SPN3 clade 1a or
5. to receive 0.9% saline for injection IM and inoculation a month later with SPN3 clade 2.
The last two 0.9% saline of injection groups represent the placebo control groups. The SPN3 (2 clades) is amoxicillin-susceptible. After challenge (inoculation) they will be followed up for 23 days where nasal, blood and urine samples will be taken. Part B of the trial will run 6 months post vaccination. Participants will be re-screened for safety prior to Part B to ensure they remain eligible. The 3 groups of participants detailed below from the Part A population will proceed to Part B of the trial:
1. Up to 104 of the participants that received PCV-13 in Part A (split across clades 1a and 2)
2. Up to 104 of the participants that received PPV-23 in Part A
3. Up to 104 of the participants that received 0.9% saline for injection in Part A (split across clades 1a and 2) The total number to proceed to Part B will be up to 312 to allow for 20% dropout / screen failure to ensure 246 complete part A \& B. All Part B Participants will receive a second inoculation of amoxicillin-susceptible SPN6B at 6 months post-vaccine and will be followed up for 23 days in total where further samples will be taken (Trial Flow Chart and Table 2). All participants will take a 5-day course of amoxicillin three times a day (TDS) at the end of Part A to ensure experimental colonization clearance prior to Part B inoculation. Participants that are experimentally colonized at any point following the SPN6B challenge at 6 months (Part B) will take a 3-day course of amoxicillin TDS.
Randomization \& Blinding: Participants will be randomized to receive PCV-13 vaccine and clade 1a (group 1), PCV-13 and clade 2 (group 2), PPV-23 vaccine and clade 1a (group 3), 0.9% saline for injection and clade 1a (group 4) or 0.9% saline for injection and clade 2 (group 5) vaccine in a ratio of 1:1:1:1:1 with up to 104 participants in each arm. Randomization will be computer-generated.
Randomization will occur in two cohorts:
1. Cohort I: 312 subjects for five groups 1:1:2:1:1 in block sizes of 6
2. Cohort II: 204 participants for four groups 1:1:0:1:1 in block sizes of 4 This will ensure that overall the randomization ratio is 1:1:1:1:1, but it will allow 312 participants from Cohort I, split equally across participants that have received PCV-13, PPV-23 and placebo to proceed to part B of the trial.
The LSTM Experimental Human Pneumococcal Challenge (EHPC) model is a unique method of measuring pneumococcal colonization of bacteria, understanding the effect of pneumococcal colonization on acquired immunity, and allows vaccines to be tested in adults to understand their effect on colonization in a manner which is cost-effective and uses much smaller numbers of participants compared to large phase III clinical trials.
Participants: Healthy adults aged 18-50 years of age (inclusive) will be recruited. A recruitment target of up to 516 participants with an approximate screen failure/dropout rate of 20% will ensure 410 participants complete Part A and 246 complete Part A \& B of the trial.
Methods: Double blind randomized controlled trial (DBRCT) to investigate the effect of PCV-13 and PPV-23 vaccination on pneumococcal colonisation using the EHPC model in healthy adults. Participants will be randomised to 5 arms for Part A of the study that:
1. to receive PCV-13 vaccine IM and inoculation a month later with SPN3 clade 1a;
2. to receive PCV-13 vaccine IM and inoculation a month later with SPN3 clade 2;
3. to receive PPV-23 vaccine IM and inoculation a month later with SPN3 clade 1a;
4. to receive 0.9% saline for injection IM and inoculation a month later with SPN3 clade 1a or
5. to receive 0.9% saline for injection IM and inoculation a month later with SPN3 clade 2.
The last two 0.9% saline of injection groups represent the placebo control groups. The SPN3 (2 clades) is amoxicillin-susceptible. After challenge (inoculation) they will be followed up for 23 days where nasal, blood and urine samples will be taken. Part B of the trial will run 6 months post vaccination. Participants will be re-screened for safety prior to Part B to ensure they remain eligible. The 3 groups of participants detailed below from the Part A population will proceed to Part B of the trial:
1. Up to 104 of the participants that received PCV-13 in Part A (split across clades 1a and 2)
2. Up to 104 of the participants that received PPV-23 in Part A
3. Up to 104 of the participants that received 0.9% saline for injection in Part A (split across clades 1a and 2) The total number to proceed to Part B will be up to 312 to allow for 20% dropout / screen failure to ensure 246 complete part A \& B. All Part B Participants will receive a second inoculation of amoxicillin-susceptible SPN6B at 6 months post-vaccine and will be followed up for 23 days in total where further samples will be taken (Trial Flow Chart and Table 2). All participants will take a 5-day course of amoxicillin three times a day (TDS) at the end of Part A to ensure experimental colonization clearance prior to Part B inoculation. Participants that are experimentally colonized at any point following the SPN6B challenge at 6 months (Part B) will take a 3-day course of amoxicillin TDS.
Randomization \& Blinding: Participants will be randomized to receive PCV-13 vaccine and clade 1a (group 1), PCV-13 and clade 2 (group 2), PPV-23 vaccine and clade 1a (group 3), 0.9% saline for injection and clade 1a (group 4) or 0.9% saline for injection and clade 2 (group 5) vaccine in a ratio of 1:1:1:1:1 with up to 104 participants in each arm. Randomization will be computer-generated.
Randomization will occur in two cohorts:
1. Cohort I: 312 subjects for five groups 1:1:2:1:1 in block sizes of 6
2. Cohort II: 204 participants for four groups 1:1:0:1:1 in block sizes of 4 This will ensure that overall the randomization ratio is 1:1:1:1:1, but it will allow 312 participants from Cohort I, split equally across participants that have received PCV-13, PPV-23 and placebo to proceed to part B of the trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Streptococcus Pneumonia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
double blind RCT
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Participants will remain blinded until the completion of the last participant, last study visit (Day 23: 7-month challenge). As the appearance of the vaccines are different, physical blindfolds may be worn by the participant to maintain blinding. This method of blinding has been used by our team previously and the time wearing the blindfold is kept to an absolute minimum for participant comfort. Un-blinded clinical team members will prepare and administer the vaccines/placebo to the participants in a blinded manner, shielding the vaccine formula, syringe and box from the participant when it is administered. The vaccine will be checked and prepared in a separate room to the participant and in a separate location to the blinded team. The participant will be seated in the vaccination room, the un-blinded clinical members will enter the vaccination room immediately prior to administration. Local SOPs will be followed to ensure appropriate participant team blinding.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PPV23
Group Type
ACTIVE_COMPARATOR
PPV23
Intervention Type
BIOLOGICAL
random allocation 1:1:1 IM injection
PCV13
Group Type
ACTIVE_COMPARATOR
PCV13
Intervention Type
BIOLOGICAL
random allocation 1:1:1 IM injection
Saline placebo
Group Type
PLACEBO_COMPARATOR
Saline for injection
Intervention Type
OTHER
random allocation 1:1:1 IM injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPV23
random allocation 1:1:1 IM injection
Intervention Type
BIOLOGICAL
PCV13
random allocation 1:1:1 IM injection
Intervention Type
BIOLOGICAL
Saline for injection
random allocation 1:1:1 IM injection
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
pneumovax
prevenar
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy adults aged 18-50 years (inclusive)
* Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement
* Capacity to provide written informed consent
* Females of childbearing potential with a negative urine pregnancy test at screening and willing to practice adequate birth control measures during the study.
* Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement
* Capacity to provide written informed consent
* Females of childbearing potential with a negative urine pregnancy test at screening and willing to practice adequate birth control measures during the study.
Exclusion Criteria
* Be currently involved in another study unless observational or non-interventional. Exceptions are the EHPC bronchoscopy study and COVID-19 observational and interventional trials. The exceptions will be applied at the discretion of the Chief Investigator to ensure no harm comes to the participants (e.g. excessive blood sampling)
* Be a participant in a previous EHPC trial within the last 3 years (at the discretion of the study team).
* Vaccination (self-reported or confirmed from GP questionnaire \[GPQ\] or medical summary if deemed necessary at clinician discretion): Have had any previous pneumococcal vaccination (including in a research study).
* Allergy:
* Have allergy to penicillin or amoxicillin.
* Have previous anaphylaxis or severe adverse reaction to any component/excipient of the vaccines or to any vaccine.
• Health history (self-reported by the participant or confirmed in GPQ or medical summary if deemed necessary at clinician discretion): Ill health including but not limited to:
* Asplenia or dysfunction of the spleen.
* Chronic respiratory disease (e.g. asthma \[on medication\], COPD, emphysema, bronchiectasis).
* Chronic heart disease (e.g. angina, ischaemic heart disease, chronic heart failure) \[controlled stable hypertension may be included\].
* Chronic kidney disease (e.g. nephrotic syndrome, kidney transplant, on dialysis).
* Chronic liver disease (e.g. cirrhosis, biliary atresia, hepatitis).
* Chronic neurological conditions
* Connective tissue disease
* Dementia
* Diabetes mellitus (including diet controlled).
* Immunosuppression or history of receiving immunosuppressive therapy.
* Individuals with cochlear implants.
* Individuals with major cerebrospinal fluid leaks (e.g. following trauma, major skull surgery, or requiring CSF shunt).
* Recurrent otitis media.
* Have any uncontrolled medical/surgical conditions (such as but not restricted to mental health conditions, epilepsy, narcolepsy or chronic pain) at the discretion of the study doctor.
* Major pneumococcal illness requiring hospitalisation within the last 10 years
* Other conditions considered by the clinical team as a concern for participant safety or integrity of the study.
* Taking medication:
* That may affect the immune system e.g. steroids, inflammation altering (e.g. nasal steroids, Roaccutane) or disease-modifying anti-rheumatoid drugs.
* Nitroglycerin
* That affects blood clotting (any oral/injectable anticoagulants \[except aspirin\]).
* Female participants who are pregnant, lactating or intending on becoming pregnant during the study.
* Direct caring role or close contact with individuals at higher risk of infection (during the challenge period)
* Children under 5 years age.
* Chronic ill health or immunosuppressed adults.
* People that are part of the extremely vulnerable group as defined by Public Health England (PHE)
• Smoker:
* Current or ex-smoker (regular cigarettes/cigars/e-cigarette/vaping/smoking of recreational drugs) in the last 6 months.
* Previous significant smoking history (more than 20 cigarettes per day for 20 years or the equivalent \[\>20 pack years\]).
* History or current drug or alcohol abuse (frequently drinking alcohol): men and women should not regularly drink \>3 units/day and \>2 units/day respectively) at discretion of the clinician.
* Significant mental health problems (uncontrolled condition or previous admission in a psychiatric unit, at the discretion of the clinician) that would impair the participant's ability to participate in the study
* Overseas travel planned: Overseas travel during the follow-up period Part A or Part B.
* Participants who meet STOP criteria at the time of screening, as detailed in Table 4.
* Any other issue which, in the opinion of the study staff, may
* Put the participant or their contacts at risk because of participation in the study,
* Adversely affect the interpretation of the study results, or
* Impair the participant's ability to participate in the study.
* Be a participant in a previous EHPC trial within the last 3 years (at the discretion of the study team).
* Vaccination (self-reported or confirmed from GP questionnaire \[GPQ\] or medical summary if deemed necessary at clinician discretion): Have had any previous pneumococcal vaccination (including in a research study).
* Allergy:
* Have allergy to penicillin or amoxicillin.
* Have previous anaphylaxis or severe adverse reaction to any component/excipient of the vaccines or to any vaccine.
• Health history (self-reported by the participant or confirmed in GPQ or medical summary if deemed necessary at clinician discretion): Ill health including but not limited to:
* Asplenia or dysfunction of the spleen.
* Chronic respiratory disease (e.g. asthma \[on medication\], COPD, emphysema, bronchiectasis).
* Chronic heart disease (e.g. angina, ischaemic heart disease, chronic heart failure) \[controlled stable hypertension may be included\].
* Chronic kidney disease (e.g. nephrotic syndrome, kidney transplant, on dialysis).
* Chronic liver disease (e.g. cirrhosis, biliary atresia, hepatitis).
* Chronic neurological conditions
* Connective tissue disease
* Dementia
* Diabetes mellitus (including diet controlled).
* Immunosuppression or history of receiving immunosuppressive therapy.
* Individuals with cochlear implants.
* Individuals with major cerebrospinal fluid leaks (e.g. following trauma, major skull surgery, or requiring CSF shunt).
* Recurrent otitis media.
* Have any uncontrolled medical/surgical conditions (such as but not restricted to mental health conditions, epilepsy, narcolepsy or chronic pain) at the discretion of the study doctor.
* Major pneumococcal illness requiring hospitalisation within the last 10 years
* Other conditions considered by the clinical team as a concern for participant safety or integrity of the study.
* Taking medication:
* That may affect the immune system e.g. steroids, inflammation altering (e.g. nasal steroids, Roaccutane) or disease-modifying anti-rheumatoid drugs.
* Nitroglycerin
* That affects blood clotting (any oral/injectable anticoagulants \[except aspirin\]).
* Female participants who are pregnant, lactating or intending on becoming pregnant during the study.
* Direct caring role or close contact with individuals at higher risk of infection (during the challenge period)
* Children under 5 years age.
* Chronic ill health or immunosuppressed adults.
* People that are part of the extremely vulnerable group as defined by Public Health England (PHE)
• Smoker:
* Current or ex-smoker (regular cigarettes/cigars/e-cigarette/vaping/smoking of recreational drugs) in the last 6 months.
* Previous significant smoking history (more than 20 cigarettes per day for 20 years or the equivalent \[\>20 pack years\]).
* History or current drug or alcohol abuse (frequently drinking alcohol): men and women should not regularly drink \>3 units/day and \>2 units/day respectively) at discretion of the clinician.
* Significant mental health problems (uncontrolled condition or previous admission in a psychiatric unit, at the discretion of the clinician) that would impair the participant's ability to participate in the study
* Overseas travel planned: Overseas travel during the follow-up period Part A or Part B.
* Participants who meet STOP criteria at the time of screening, as detailed in Table 4.
* Any other issue which, in the opinion of the study staff, may
* Put the participant or their contacts at risk because of participation in the study,
* Adversely affect the interpretation of the study results, or
* Impair the participant's ability to participate in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Sponsor Role
collaborator
Liverpool School of Tropical Medicine
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liverpool School of Tropical Medicine
Liverpool, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
angela hyder wright
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Liatsikos K, Hyder-Wright A, Pojar S, Chen T, Wang D, Davies K, Myerscough C, Reine J, Robinson RE, Urban B, Mitsi E, Solorzano C, Gordon SB, Quinn A, Pan K, Anderson AS, Theilacker C, Begier E, Gessner BD, Collins A, Ferreira DM; PNEUMO 2 study group. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2). BMJ Open. 2022 Jul 7;12(7):e062109. doi: 10.1136/bmjopen-2022-062109.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00427895
COMPLETED
PHASE3
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288
COMPLETED
PHASE2
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713
COMPLETED
PHASE3
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
NCT01619462
UNKNOWN
PHASE3
Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT05092386
COMPLETED
PHASE1
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
NCT02116998
COMPLETED
PHASE2
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
COMPLETED
PHASE3
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677
RECRUITING
PHASE1
Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
NCT00508742
COMPLETED
PHASE3
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
NCT02451969
COMPLETED
PHASE3
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
NCT03760146
COMPLETED
PHASE3
Pneumococcal Vaccines Early and in Combination
NCT01174849
COMPLETED
PHASE4
PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae
NCT02133469
COMPLETED
NA
Understanding Pneumococcal Carriage and Disease 2017-2020
NCT03102840
UNKNOWN
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults
NCT01767402
COMPLETED
PHASE1
Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study
NCT04401488
UNKNOWN
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328
COMPLETED
PHASE1
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07025876
COMPLETED
EARLY_PHASE1
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
NCT01109108
COMPLETED
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414
ACTIVE_NOT_RECRUITING
PHASE2
Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers
NCT02279589
COMPLETED
PHASE2
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
NCT03549208
UNKNOWN
PHASE1
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
NCT00580684
COMPLETED
PHASE4
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
NCT03547167
COMPLETED
PHASE3
Understanding Pneumococcal Carriage and Disease
NCT01996007
COMPLETED